Stevanato Group S.p.A., a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced its financial results for the fourth quarter 2021.
Fourth Quarter and Full Year Highlights (compared to the same period last year)
- Fourth quarter revenue increased 12.5 percent to EUR 232.6 million, diluted EPS were EUR 0.17 and adjusted diluted EPS were EUR 0.13. Adjusted EBITDA margin was 25.3 percent,
- Full year revenue grew 27.5 percent to EUR 843.9 million, diluted EPS were EUR 0.53 and adjusted diluted EPS were EUR 0.48. Adjusted EBITDA margin increased to 25.9 percent,
- Backlog increased to EUR 880 million,
- Revenue from high value solutions increased to 28.5 percent and 24.6 percent of total revenue for the fourth quarter and full year, respectively,
- The Company established fiscal year 2022 guidance and expects revenue in the range of EUR 935.0 million to EUR 945.0 million, adjusted diluted earnings per share between EUR 0.49 to EUR 0.51 and adjusted EBITDA in the range of EUR 248.0 million to EUR 253.0 million.
To read the full, report click here.